Funding:

Novartis Pharmaceuticals

Description

Remibrutinib inhibits an enzyme called “Bruton’s tyrosine kinase,” reducing the activation of B cells, which are immune cells that play a role in the response that affects the brain and spinal cord in MS.  This study is comparing the safety and effectiveness of oral Remibrutinib to oral Aubagio® (teriflunomide, Genzyme Sanofi). Participants will undergo blood draws, MRI scans of the brain, and study visits. A stipend will be provided for time and travel.